Serial 2-Point Ultrasonography Plus D-Dimer vs Whole-Leg Color-Coded Doppler Ultrasonography for Diagnosing Suspected Symptomatic Deep Vein Thrombosis
A Randomized Controlled Trial

Enrico Bernardi, MD, PhD
Giuseppe Camporese, MD
Harry R. Büller, MD, PhD
Sergio Siragusa, MD
Davide Imberti, MD
Arrigo Berchio, MD
Angelo Ghirarduzzi, MD
Fabio Verlato, MD
Raffaele Anastasio, MD
Carolina Prati, MD
Andrea Piccioli, MD
Raffaele Pesavento, MD
Carlo Bova, MD
Patrizia Maltempi, MD
Nello Zanatta, MD
Alberto Cogo, MD, PhD
Roberto Cappelli, MD
Eugenio Bucherini, MD
Stefano Cuppini, MD
Francesco Noventa, MD
Paolo Prandoni, MD, PhD
for the Erasmus Study Group

Context  Patients with suspected deep vein thrombosis (DVT) of the lower extremities are usually investigated with ultrasonography either by the proximal veins (2-point ultrasonography) or the entire deep vein system (whole-leg ultrasonography). The latter approach is thought to be better based on its ability to detect isolated calf vein thrombosis; however, it requires skilled operators and is mainly available only during working hours. No randomized comparisons are yet available evaluating the relative values of these 2 strategies.

Objective  To assess if the 2 diagnostic strategies are equivalent for the management of symptomatic outpatients with suspected DVT of the lower extremities.

Design, Setting, and Patients  A prospective, randomized, multicenter study of consecutive symptomatic outpatients (n = 2465) with a first episode of suspected DVT of the lower extremities who were randomized to undergo 2-point or whole-leg ultrasonography. Data were taken from ultrasound laboratories of 14 Italian universities or civic hospitals between January 1, 2003, and December 21, 2006. Patients with normal ultrasound findings were followed up for 3 months, with study completion on March 20, 2007.

Main Outcome Measure  Objectively confirmed 3-month incidence of symptomatic venous thromboembolism in patients with an initially normal diagnostic workup.

Results  Of 2465 eligible patients, 345 met 1 or more exclusion criteria and 22 refused to participate; therefore, 2098 patients were randomized to either 2-point (n = 1045) or whole-leg (n = 1053) ultrasonography. Symptomatic venous thromboembolism occurred in 7 of 801 patients (incidence, 0.9%; 95% confidence interval [CI], 0.3%-1.8%) in the 2-point strategy group and in 9 of 763 patients (incidence, 1.2%; 95% CI, 0.5%-2.2%) in the whole-leg strategy group. This met the established equivalence criterion (observed difference, 0.3%; 95% CI, −1.4% to 0.8%).

Conclusion  The 2 diagnostic strategies are equivalent when used for the management of symptomatic outpatients with suspected DVT of the lower extremities.

Trial Registration  The 2 diagnostic strategies are equivalent when used for the management of symptomatic outpatients with suspected DVT of the lower extremities.

©2008 American Medical Association. All rights reserved.

(Reprinted) JAMA, October 8, 2008—Vol 300, No. 14 1653
at presentation to detect calf DVT extending to the proximal veins (serial 2-point ultrasonography).\(^2,8\) Repeat testing may be safely avoided in patients with a normal D-dimer test result at presentation.\(^6,8,10,11\)

The newer color-coded Doppler ultrasound scanners allow the evaluation of the entire deep venous system, from the groin to the ankle (whole-leg ultrasonography). With this strategy, color flow artifacts are exploited to enhance small vessel visualization, although vein compressibility still constitutes the main diagnostic criterion. The advantage of this approach is the ability to exclude isolated calf DVT, allowing for 1-day treatment of all patients, without additional testing.\(^12-15\) Conventional testing, especially in the everyday practice of ultrasound laboratories, based on the assumption that detecting isolated calf DVT is a clinically relevant issue.\(^18,19\) As a consequence, many patients with suspected DVT need to wait hours or even days before whole-leg ultrasonography is obtainable\(^16,17\) and are frequently (unnecessarily) administered anticoagulants in the meantime.\(^16,20\)

Recent observations challenge this view and claim that prompt detection of calf DVT may not be as relevant as previously believed.\(^21-24\) Conversely, the systematic evaluation of the calf vein system may bring about a definite risk of overtreating thrombi that may otherwise heal spontaneously.\(^15,25\)

To test the hypothesis that the 2 diagnostic strategies are equivalent for the exclusion of a first episode of suspected DVT in symptomatic outpatients, we undertook a prospective, randomized, multicenter study assessing the incidence of symptomatic venous thromboembolism (VTE) during a 3-month follow-up period in patients spared anticoagulation on the basis of a normal initial workup with either serial 2-point ultrasonography plus D-dimer (2-point strategy) or whole-leg color-coded Doppler ultrasonography (whole-leg strategy).

**METHODS**

**Patients**

All consecutive outpatients who were referred by the emergency department or a primary care physician to 1 of the 14 study centers (all ultrasound laboratories located in Italy) with a first episode of suspected symptomatic DVT of the lower extremities were eligible for inclusion. Exclusion criteria included pregnancy, age younger than 18 years, history of VTE, suspected pulmonary embolism, life expectancy of less than 3 months, ongoing anticoagulation (>48 hours), mandatory indication for anticoagulation (e.g., atrial fibrillation), and geographic inaccessibility to follow-up. Patients were enrolled between January 1, 2003, and December 21, 2006, with study completion on March 20, 2007. The study was conducted according to the ethical principles stated in the Declaration of Helsinki, and the protocol was approved by the institutional review board of each participating center.

**Randomization**

Eligible patients, after signing a written informed consent form, were assigned to either the 2-point or the whole-leg strategy. The investigators had to contact the coordinating center by telephone to obtain the patient’s group allocation. A randomization list was available for each center, arranged by blocks of 10 patients to ensure balancing (generated by nQuery functionality \[nQuery Advisor; Statistical Solutions Ltd, Cork, Ireland\]).

**Study Outline**

**Two-Point Strategy.** Patients with normal ultrasound findings at presentation underwent D-dimer testing. Patients with normal D-dimer levels were spared further investigation and were not anticoagulated. Patients with abnormal D-dimer levels were scheduled for a repeat ultrasonography at 1 week, or earlier if clinically indicated. Those patients with normal repeat ultrasound findings were spared further investigation and were not anticoagulated.

**Whole-Leg Strategy.** Patients with normal ultrasound results at presentation were spared further investigation and were not anticoagulated.

**Follow-up.** Patients with normal findings at the initial diagnostic workup were scheduled for an end of follow-up visit after 3 months, which consisted of (1) a standardized interview to assess their general health status, chest or leg complaints, and history of hospital admission for any cause; (2) a physical examination; and (3) an ultrasonographic evaluation. Patients were instructed to refer to the study centers immediately if they experienced syncope, shortness of breath, chest pain, palpitations, and either new or worsening leg symptoms. Patients who did not attend the scheduled visit were contacted by telephone by the investigators and interviewed using a standardized questionnaire to assess their general health status, chest or leg complaints, and history of hospital admission for any cause.

**Interventions**

All diagnostic evaluations were performed by certified physicians with long-standing experience in vascular ultrasonography.

**Two-Point Strategy.** Two-point ultrasoundography was performed and interpreted as described elsewhere.\(^2-4\)

Briefly, the common femoral at the groin and the popliteal vein down to its branching into the calf deep veins at the popliteal fossa were examined in the transverse plane with a linear probe (5-10 MHz). Vein incompressibility was the only diagnostic criterion applied. Test results were categorized as normal (compressible veins) or abnormal (noncompressible veins).

D-dimer testing was evaluated by using a rapid whole-blood bedside D-dimer assay (SimpliRED D-Dimer; AGEN Biomedical Ltd, Brisbane, Australia), which was based on red blood
cells agglutination. Results were categorized as normal (no visible agglutination) or abnormal (visible agglutination or noninterpretable findings).

Whole-Leg Strategy. Lacking a widely accepted protocol for whole-leg ultrasonography, the standard procedure for the study purposes was agreed a priori by all investigators during a consensus meeting held before the beginning of the study. All veins were imaged continuously along their length, in the transverse plane, with a linear probe (5-10 MHz). The proximal deep veins were examined first, including the femoral veins (common, superficial, and deep) and the popliteal vein down to its trifurcation. Then, only in patients with normal proximal findings, the calf veins were evaluated, including the axial (peroneal and posterior tibial) and the muscular veins. Vein incompressibility was the sole diagnostic criterion adopted for abnormal testing of the proximal and axial calf veins. Adjunctive criteria for abnormal ultrasonography, the standard procedure for the study purposes was agreed a priori by all investigators during a consensus meeting held before the beginning of the study. All veins were imaged continuously along their length, in the transverse plane, with a linear probe (5-10 MHz). The proximal deep veins were examined first, including the femoral veins (common, superficial, and deep) and the popliteal vein down to its trifurcation. Then, only in patients with normal proximal findings, the calf veins were evaluated, including the axial (peroneal and posterior tibial) and the muscular veins. Vein incompressibility was the sole diagnostic criterion adopted for abnormal testing of the proximal and axial calf veins. Adjunctive criteria for abnormal ultrasonography, were not anticoagulated and were followed up for 3 months. Of the 1053 patients randomized to the whole-leg strategy, 278 (26.4%; 95% CI, 23.7%-29.1%) had abnormal ultrasound findings at presentation. Of these, 213 patients (76.6%) had proximal DVT, 36 patients (13.0%) had isolated axial (posterior tibial or peroneal) DVT, and 29 patients (10.4%) had isolated muscular vein thrombosis. The remaining 775 patients with normal ultrasound findings were not anticoagulated and were followed up for 3 months.

Three-Month Follow-up

TABLE 2 shows the type, timing, diagnostic method used, and location of the
outcome events that occurred during the 3 months of follow-up. Of 814 patients allocated to the 2-point strategy, 9 (1.1%) died during follow-up, because of cancer (n=5), brain hemorrhage (n=1), ischemic stroke (n=1), myocardial infarction (n=1), and heart failure (n=1); and 4 patients (0.5%) were lost to follow-up (unknown whereabouts). Sixteen patients had suspected symptomatic VTE during the follow-up period, which was objectively confirmed in 7 patients and not found in 9 patients. Therefore, in this group, the incidence of confirmed symptomatic VTE during the 3-month follow-up period was 0.9% (95% CI, 0.3%-1.8%). Of 785 patients eligible for the clinical and instrumental end of follow-up visit, 189 (24%) regularly presented to the clinics and 596 (76%) were interviewed by telephone.

Of 775 patients randomized to the whole-leg strategy, 7 (0.9%) died during follow-up, because of cancer (n=5), massive trauma (n=1), and myocardial infarction (n=1); and 5 patients (0.6%) were lost to follow-up (unknown whereabouts). Twenty-one patients had suspected symptomatic VTE during the follow-up period, which was objectively confirmed in 9 patients and not found in 12 patients. Therefore, the incidence of confirmed symptomatic VTE during the 3-month follow-up period was 1.2% (95% CI, 0.5%-2.2%). Of 742 patients eligible for the clinical and instrumental end of follow-up visit, 172 (23%) regularly presented to the clinics and 570 (77%) were interviewed by telephone.

The observed difference between the 2 groups in terms of symptomatic VTE at the end of the 3-month follow-up period was 0.3% (95% CI, −1.4% to 0.8%), which is within the chosen equivalence limit. The sensitivity analysis, including patients who died during the study and/or were lost to follow-up, did not yield different results from the main analysis.

**COMMENT**

Our study shows that the 2-point and whole-leg strategies are equivalent for the management of symptomatic patients with suspected DVT. The 3-month incidence of objectively confirmed VTE in patients with an initial normal diagnostic ultrasound was similar in the 2 study groups. Furthermore, the observed data are consistent with those reported in previous large cohort studies.3-8,11-14

Two specific issues deserve further discussion. First, despite a significantly higher initial prevalence of DVT in the whole-leg group compared with the 2-point group (absolute difference, 4.3%; 95% CI, 0.5%-8.1%), the long-term outcome of the patients was quite similar. Interestingly, that difference was entirely accounted for by 65
cases of isolated calf DVT identified by whole-leg ultrasonography; thus, one might speculate that detecting isolated calf DVT may not be as relevant as previously believed. However, because objectively diagnosed symptomatic calf DVT requires full anticoagulation and still awaiting confirmation, is indirectly supported by the findings of a recent randomized trial and of several cohort studies. In these studies, which routinely investigated the calf veins, the reported incidence of thromboembolic events after 3 to 6 months of follow-up in patients spared anticoagulants on the basis of a normal ultrasound is fully comparable with that observed in studies which did not investigate the calf veins. A properly designed randomized study is necessary to address this issue in a formally and scientifically correct fashion.

Second, the thorough evaluation of the femoral veins (common, superficial, or deep) and of the popliteal vein did not increase the overall diagnostic yield of the whole-leg strategy. The initial prevalence of proximal DVT was similar in both groups (22.1% in the 2-point strategy group vs 20.2% in the whole-leg strategy group). This finding confirms that, in symptomatic outpatients, proximal DVT always involves the common femoral vein, the popliteal vein, or both; and therefore the superficial and deep femoral veins are usually not worth investigating.

Our results were obtained using adequate methods. All consecutive symptomatic patients referred to the participating centers were eligible for inclusion in the study. Confounding

### Table 1. Demographic and Clinical Characteristics of the Study Patients at Presentation

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Two-Point Strategy (n = 1045)</th>
<th>Whole-Leg Strategy (n = 1053)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age, mean (SD), y</td>
<td>63.7 (16.3)</td>
<td>62.5 (16.2)</td>
</tr>
<tr>
<td>Male sex, No. (%)</td>
<td>439 (42.0)</td>
<td>430 (40.8)</td>
</tr>
<tr>
<td>Obesity (BMI ≥ 30), No. (%)</td>
<td>157 (15.0)</td>
<td>165 (15.7)</td>
</tr>
<tr>
<td>Current smoker, No. (%)</td>
<td>93 (8.9)</td>
<td>74 (7.0)</td>
</tr>
</tbody>
</table>

### Table 2. Distribution and Timing of Venous Thromboembolic Events

<table>
<thead>
<tr>
<th>Allocation Group</th>
<th>End Points</th>
<th>Timing, d</th>
<th>Diagnostic Method</th>
<th>DVT Site</th>
</tr>
</thead>
<tbody>
<tr>
<td>Two-point strategy Ipsilateral DVT</td>
<td>10</td>
<td>Ultrasonography</td>
<td>Proximal</td>
<td></td>
</tr>
<tr>
<td>Ipsilateral DVT</td>
<td>12</td>
<td>Ultrasonography</td>
<td>Proximal</td>
<td></td>
</tr>
<tr>
<td>Ipsilateral DVT</td>
<td>21</td>
<td>Ultrasonography</td>
<td>Proximal</td>
<td></td>
</tr>
<tr>
<td>Ipsilateral DVT</td>
<td>66</td>
<td>Ultrasonography</td>
<td>Isolated calf</td>
<td></td>
</tr>
<tr>
<td>Ipsilateral DVT</td>
<td>81</td>
<td>Ultrasonography</td>
<td>Isolated calf</td>
<td></td>
</tr>
<tr>
<td>Whole-leg strategy Pulmonary embolism</td>
<td>2</td>
<td>V/Q lung scan and computed tomography</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Contralateral DVT</td>
<td>18</td>
<td>Ultrasonography</td>
<td>Isolated calf</td>
<td></td>
</tr>
<tr>
<td>Ipsilateral DVT</td>
<td>42</td>
<td>Ultrasonography</td>
<td>Proximal</td>
<td></td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>48</td>
<td>V/Q lung scan</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Ipsilateral DVT</td>
<td>54</td>
<td>Ultrasonography</td>
<td>Proximal</td>
<td></td>
</tr>
<tr>
<td>Pulmonary embolism</td>
<td>68</td>
<td>Computed tomography</td>
<td>NA</td>
<td></td>
</tr>
<tr>
<td>Ipsilateral DVT</td>
<td>88</td>
<td>Ultrasonography</td>
<td>Proximal</td>
<td></td>
</tr>
<tr>
<td>Contralateral DVT</td>
<td>88</td>
<td>Ultrasonography</td>
<td>Proximal</td>
<td></td>
</tr>
<tr>
<td>Ipsilateral DVT</td>
<td>92</td>
<td>Ultrasonography</td>
<td>Isolated calf</td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: DVT, deep vein thrombosis; NA, not applicable; V/Q, ventilation-perfusion.

Two-point strategy indicates serial 2-point ultrasonography plus D-dimer; whole-leg strategy indicates whole-leg color-coded Doppler ultrasonography.

Time elapsed from onset of symptoms to patient presentation.

The total number of women was 606 for 2-point strategy and 623 for whole-leg strategy.

©2008 American Medical Association. All rights reserved.
factors were minimized by excluding patients with a history of previous VTE. Demographic characteristics and risk factors for DVT were evenly distributed in the 2 study groups. Patients randomized to the 2-point strategy were treated according to a highly standardized method.3,4,7,8 The D-miss assay we used has a high reproducibility and negative predictive value in clinically symptomatic patients.10,26,33 Lacking a widely accepted protocol for whole-leg ultrasonography, all investigators agreed a priori the evaluation technique and the diagnostic criteria to be used. Only experienced physicians did ultrasonography. Follow-up was performed prospectively, and predefined criteria were applied to diagnose symptomatic VTE. Only a minority (0.6%) of the patients with a normal initial workup were lost to follow-up; although among the patients who completed the 3-month period of observation, approximately 75% were contacted by telephone and approximately 25% were seen in the clinics for a clinical and instrumental evaluation. The latter finding may be regarded as a potential limitation, although telephone interviews quite commonly substitute for end-of-follow-up visits, especially when patients’ samples are large.11,13,14 However, patients often fail to present for repeat testing, for various reasons.14 Given that the characteristics of the study patients and the rate of both initial and long-term DVT were consistent with those reported by previous similar studies,3,8,11,13,14 our results are likely to be valid and generalizable.

In conclusion, both serial 2-point ultrasonography plus D-miss and whole-leg color-coded Doppler ultrasonography represent reliable diagnostic options for the management of symptomatic patients with suspected DVT of the lower extremities. Either strategy may be chosen based on the clinical context, on the patients’ needs, and on the available resources. The former is simple, convenient, and widely available but requires repeat testing in one-fourth of the patients. The latter offers a 1-day answer, desirable for patients with severe calf complaints, for travelers, and for those living far from the diagnostic service, but is cumbersome, possibly more expensive, and may expose patients to the risk of (unnecessary) anticoagulation.

Author Affiliations: Department of Emergency and Accident Medicine, Civic Hospital, Cosenza, Italy (Dr Bernardi); Angiography Unit (Drs Camporese and Verlato), Department of Medical and Surgical Sciences (Drs Piccioli and Prandoni), and Department of Clinical and Experimental Medicine, Group of Clinical Epidemiology (Dr Noventa), University Hospital, Padua, Italy; Department of Vascular Medicine, Academic Medical Center, University of Amsterdam, Amsterdam, the Netherlands (Dr B Müller); and Service of Haemostasis and Thrombosis, University Hospital, Palermo (Drs Siragusa and Anastasio); Center for Haemostasis and Thrombosis, Department of Emergency and Accident Medicine, Civic Hospital, Placenza (Drs Imberti and Prati); Department of Emergency and Accident Medicine, S Giovanni Battista Hospital, Torino (Dr Berchio); Angiology Unit, Department of Internal Medicine, S Maria Nuova Hospital, Reggio Emilia (Dr Ghirarduzzi); Department of Internal Medicine, Civic Hospital, Castelfranco Veneto (Dr Pesavento); Department of Medicine, Civic Hospital, Cosenza (Dr Bova); Department of Surgical Sciences, S Carlo Borromeo Hospital, Milan (Dr Maltoni); Department of Internal Medicine, Civic Hospital, Vittorio Veneto (Dr Zanatta); Department of Vascular Medicine, Villa Berica Hospital, Vicenza (Dr Cogo); Department of Internal, Cardiovascular and Genitourinary Medicine, Policlinico “Le Scotte.” Siena (Dr D’Appollonio); Angiology Unit, Civic Hospital, Faenza (Dr Bucherini); Department of Internal Medicine, Civic Hospital, Rovigo (Dr Cuppini), Italy.

Author Contributions: Drs Bernardi and Camporese had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Study concept and design: Bernardi, Piccioli, Prandoni. Acquisition of data: Bernardi, Camporese, Siragusa, Imberti, Berchio, Ghirarduzzi, Verlato, Anastasio, Prati, Pesavento, Berchio, Maltoni, Zanatta, Cogo, Cappelli, Bucherini, Cuppini. Analysis and interpretation of data: Bernardi, Camporese, B Müller, Imberti, Prati, Novventa, Prandoni. Drafting of the manuscript: Bernardi, Camporese, B Müller, Berchio, Novventa, Prandoni. Critical revision of the manuscript for important intellectual content: Bernardi, Camporese, B Müller, Siragusa, Imberti, Ghirarduzzi, Verlato, Anastasio, Prati, Piccioli, Pesavento, Bova, Maltoni, Zanatta, Cogo, Cappelli, Bucherini, Cuppini, Novventa, Prandoni. Statistical analysis: Bernardi, Novventa. Administrative, technical, or material support: Bernardi, Camporese.

Study supervision: Bernardi, Camporese, B Müller, Imberti, Verlato, Prati, Piccioli, Pesavento, Novventa, Prandoni.

Financial Disclosures: None reported.

Members of the Erasmus Study Group (Italy): Angiology Unit, University Hospital, Padua: Laura Zotta, MD, Francesca Franz, MD, Claudia Chiarion, MD; Mariaberesa Bovi, MD, Giuseppe Andreozzi, MD; Service of Haemostasis and Thrombosis, University Hospital, Palermo: Alessandra Malato, MD, Lucio Lo Coco, MD, Giacomo Millo, MD, Oreste Cornaci, MD; Center for Haemostasis and Thrombosis, Department of Emergency and Accident Medicine, Civic Hospital, Placenza: Pietro Cavallotti, MD, Sergio Orlando, MD; Department of Emergency and Accident Medicine, S Giovanni Battista Hospital, Torino: Elia Rofo, MD, Carlo Valenzano, MD; Angiology Unit, Department of Internal Medicine, S Maria Nuova Hospital, Reggio Emilia: Matteo Iotti, MD, Mari leasta, MD, Department of Angiology, Civic Hospital, Castelfranco Veneto: Adriana Visionà, MD, Francesca Sala, MD, Antonio Pagnan, MD; Department of Medicine, Civic Hospital, Cosenza: Roberto Ricosio, MD, Alfonso Noto, MD; Department of Surgical Sciences, S Carlo Borromeo Hospital, Milan: Pier G. Settembrini, MD; Department of Internal Medicine, Civic Hospital, Vittorio Veneto: Massimo Sanfus, MD, Domenico Mogol, MD; Department of Internal, Cardiovascular, and Geriatric Medicine, Policlinico “Le Scotte.” Siena: Maurizio Bichi, MD, Francesca Maggi, MD; Department of Internal Medicine, Civic Hospital, Rovigo: Stefano Zamboni, MD; Department of Medical and Surgical Sciences, University, Padua: Ugo Baccaglini, MD, Giuseppe Spreafico, MD.

Funding/Support: This study project was awarded to Dr Bernardi by SISET (Società Italiana per lo Studio dell’Emostasi e della Trombosi). The AGEN Biomedical Ltd (Brisbane, Australia) provided the D-miss testing kits free-of-charge.

Role of the Sponsor: The AGEN Biomedical Ltd had no role in the design and conduct of the study, in the collection, analysis, or interpretation of the data, or in the preparation, review, or approval of the manuscript.

Previous Presentation: This study was presented in part as an oral communication at the XXIII Congress of the International Society on Thrombosis and Haemostasis; July 6-12, 2007, Geneva, Switzerland.

REFERENCES

ULTRASONOGRAPHY FOR DIAGNOSING SUSPECTED SYMPTOMATIC DVT


